Devonian Announces that its Subsidiary, Altius, Launches Authorized Generic of Dexlansoprazole (Dexilant®) in Canada
TWi`s Generic Dexlansoprazole Receives Approval in the U.S.
Par Pharm’s Generic Dexlansoprazole Receives Approval In US
Takeda’s Dexlansoprazole Received Approval In US
The nationwide law firm of Bernstein Liebhard LLP has launched a new Nexium lawsuit investigation, following the publication of two studies which found that the use of proton pump inhibitors may be associated with an increased risk of chronic kidney disease and kidney failure. The Firm is now offering free, no-obligation legal reviews to anyone who was diagnosed with serious kidney complications, including kidney disease, renal failure or acute interstitial nephritis, following treatment with Nexium or other proton pump inhibitors.
Takeda Pharmaceuticals U.S.A., Inc., (Takeda) (TSE: 4502) today announced that the United States (U.S.) Food and Drug Administration (FDA) approved Dexilant SoluTab delayed-release orally disintegrating tablets, a new formulation of dexlansoprazole that can be taken by allowing the tablet to melt in the patient's mouth. Dexilant SoluTab is a proton pump inhibitor (PPI) indicated for the treatment of heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GERD) and the maintenance of healed erosive esophagitis (EE) and relief of heartburn in adults 18 years and older. Dexilant SoluTab is a PPI with dual delayed release (DDR) technology that is designed to provide two separate releases of medication.
TWi signs Settlement Agreement with Takeda on patent litigation related to generic Dexilant